News Search Results
May 06, 2025, 07:30 ET Factor Bioscience to Present Non-Viral Gene Editing and Cell Engineering Innovations at the ASGCT Annual Meeting
May 6, 2025 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation
More news about: Factor Bioscience
May 06, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
webcast will be available for approximately 30 days following the presentation. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered
More news about: REGENXBIO Inc.
May 06, 2025, 07:03 ET Trailhead Biosystems Secures $20 Million to Drive Innovation and Accelerate Growth
www.trailbio.com), a biotechnology company advancing human cell innovation, has secured $20 million in financing. Trailhead specializes in precisely
More news about: Trailhead Biosystems Inc
May 06, 2025, 07:00 ET Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
(289) 819-1450 (International) and using replay code: 28038#. About Oncolytics Biotech Inc.Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
May 06, 2025, 07:00 ET "Gedeon Richter House of Hope" opens its doors to support 300 women annually in Africa-Bamako
Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing
More news about: Gedeon Richter Plc.
May 06, 2025, 07:00 ET Ascidian Therapeutics Announces Formation of Scientific Advisory Board
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the formation of its Scientific Advisory Board (SAB). These globally recognized
More news about: Ascidian Therapeutics
May 06, 2025, 06:18 ET Celebrating the 25th Global Family Office Investment Summit Hosted by Anthony Ritossa
transformation in just five years. Exponential advancements in artificial intelligence, immersive computing, decentralized finance, and biotechnology are redefining the way we live, work, and invest. Unlimited Awesome is building the next generation of innovators and change-makers." "The
More news about: Ritossa Family Office
May 06, 2025, 06:05 ET IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
sector on capital markets transactions, corporate strategy and other investment banking services representing more than $65 billion of value for biotechnology companies worldwide.Shanthakumar Tyavanagimatt, Ph.D., joined IDEAYA as Senior Vice President, Technical Operations, where he will lead
More news about: IDEAYA Biosciences, Inc.
May 06, 2025, 05:45 ET Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA
May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
May 06, 2025, 03:00 ET TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic
More news about: TFS HealthScience
May 06, 2025, 03:00 ET TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic
More news about: TFS HealthScience
May 06, 2025, 01:30 ET Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the Mexican patent office has issued a notice of allowance for the Company's patent application covering
More news about: Innocan Pharma Corporation
May 06, 2025, 01:30 ET Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the Mexican patent office has issued a notice of allowance for the Company's patent application covering
More news about: Innocan Pharma Corporation
May 06, 2025, 01:00 ET Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the successful completion of US$45
More news about: Nuevocor
May 05, 2025, 17:31 ET Intravenous Immunoglobulin (IVIG) Market Forecast to Surge During the Forecast Period (2025-2034) with Rising Demand for Autoimmune and Immunodeficiency Treatments | DelveInsight
experiencing significant growth due to the rising prevalence of autoimmune diseases, immune deficiencies, and neurological disorders. Advancements in biotechnology and an increased focus on personalized medicine are driving innovation in IVIG therapies. LAS
More news about: DelveInsight Business Research, LLP
May 05, 2025, 17:15 ET Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
May 05, 2025, 12:47 ET Lilly declares second-quarter 2025 dividend
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 05, 2025, 11:20 ET Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline project: a unique and innovative co-development
More news about: Odylia Therapeutics
May 05, 2025, 10:57 ET Breakthrough Alzheimer's Vaccine Duvax Secures $3 Million NIH Grant to Launch U.S. Clinical Trials
Nuravax Inc., a biotechnology company pioneering immunotherapy for neurodegenerative disorders, has been awarded a $3 million grant from the National
More news about: Nuravax Inc
May 05, 2025, 09:00 ET Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
LinkedIn. About Optieum BiotechnologiesOptieum Biotechnologies Inc. is a cutting-edge biotechnology company dedicated to engineering hope for patients through the development of next-generation CAR-T cell therapies. At the heart of Optieum's innovation
More news about: Genezen
May 05, 2025, 08:08 ET Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
YORK, May 5, 2025 /PRNewswire/ -- IGI, a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track
More news about: Ichnos Glenmark Innovation
May 05, 2025, 08:00 ET Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators
COLLEGE STATION, Texas, May 5, 2025 /PRNewswire/ -- Matica Biotechnology, a specialized contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT), has entered into a strategic partnership
More news about: Matica Biotechnology, Inc.
May 05, 2025, 08:00 ET Orna Therapeutics Announces Presentation at the American Society of Gene and Cell Therapy Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases
WATERTOWN, Mass., May 5, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced an upcoming presentation
More news about: Orna Therapeutics
May 05, 2025, 08:00 ET Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
May 5, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
More news about: Spyre Therapeutics, Inc.
May 05, 2025, 08:00 ET Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.